Who are BRM424 Ophthalmic Solution - Dose1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PAL, Total coumarin (TC) cream, KPI-121 Ophthalmic Suspension.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/brm424-ophthalmic-solution-dose1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BRM424 Ophthalmic Solution - Dose1 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BRM424 Ophthalmic Solution - Dose1 (BRM424 Ophthalmic Solution - Dose1) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical anti-inflammatory. Area: Ophthalmology.

phase 2 Topical anti-inflammatory Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

BRM424 Ophthalmic Solution - Dose1 (BRM424 Ophthalmic Solution - Dose1) — BRIM Biotechnology Inc.. BRM424 Ophthalmic Solution is a topical anti-inflammatory agent.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BRM424 Ophthalmic Solution - Dose1 TARGET	BRM424 Ophthalmic Solution - Dose1	BRIM Biotechnology Inc.	phase 2	Topical anti-inflammatory
PAL	PAL	Folia Biotech Inc.	marketed	Topical anti-inflammatory/analgesic	PPAR-α; endocannabinoid system
Total coumarin (TC) cream	Total coumarin (TC) cream	Psoriasis Research Institute of Guangzhou	phase 3	Herbal/botanical topical anti-inflammatory
KPI-121 Ophthalmic Suspension	KPI-121 Ophthalmic Suspension	Kala Pharmaceuticals, Inc.	phase 3	TRPV1 antagonist / Topical anti-inflammatory	TRPV1 (Transient Receptor Potential Vanilloid 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical anti-inflammatory class)

Aldeyra Therapeutics, Inc. · 1 drug in this class
BRIM Biotechnology Inc. · 1 drug in this class
BioCis Pharma Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BRM424 Ophthalmic Solution - Dose1 — Competitive Intelligence Brief. https://druglandscape.com/ci/brm424-ophthalmic-solution-dose1. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing